海外の治験の状況「1」での検索結果
379件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A clinical study investigating the efficacy, tolerability and safety of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with a diagnosis of bipolar I disorder
- Treatment of Manic Episodes Associated with Bipolar I Disorder MedDRA version: 20.0 Level: LLT Classification code 10068455 Term: Bipolar I disorder, hypomanic System Organ Class: 100000004873 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Bulgaria, Poland, Serbia, United States
- 2018-01-15
Authorised
- A Study to evaluate the Effect and Safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Renal Impairment
- Chronic HCV Genotype 1-6 Infection MedDRA version: 19.0 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Belgium, Canada, France, Greece, Italy, New Zealand, United Kingdom, United States
- 2015-11-03
Authorised
- Phase 2 study of lenvatinib plus pembrolizumab for advanced melanoma in anti-PD-1/L1-exposed participants
- Advanced melanoma MedDRA version: 20.0 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, Spain, Sweden, United States
- 2018-10-22
Authorised
- This is an open-label, multi-center, dose escalation Phase 1/2a study to establish the recommended dose for Phase 2 (RP2D) from Phase 1a and Phase 1b, as well as evaluating the preliminary efficacy of the RP2D in expansion cohorts (Phase 2a) in patients with liver related cancers.
- hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), or, metastatic liver disease MedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10073077 Term: Intrahepatic cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10027479 Term: Metastatic liver carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, Korea, Republic of, United Kingdom, United States
- 2018-08-09
Authorised
- Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
- Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Italy, Korea, Republic of, Lithuania, Malaysia, New Zealand, Poland, Portugal, Spain, Turkey, United Kingdom, United States
- 2018-07-30
Authorised
- Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
- Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom, United States
- 2018-07-17
Authorised
- OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)
- IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Canada, Hungary, Lithuania, United States
- 2018-04-23
Authorised
- A study in which the safety and efficacy of Nefecon is compared with placebo in patients with primary IgA Nephropathy.
- Primary IgA nephropathy patients at risk of developing end stage renal disease MedDRA version: 20.0 Level: LLT Classification code 10069341 Term: Berger's disease System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belarus, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Korea, Republic of, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2018-03-02
Authorised
- A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.
- Progressive Familial Intrahepatic Cholestasis Types 1 and 2 MedDRA version: 20.0 Level: PT Classification code 10076033 Term: Progressive familial intrahepatic cholestasis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Saudi Arabia, Spain, Sweden, Turkey, United Kingdom, United States
- 2018-02-19
Authorised
- Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
- Diabetic Foot Ulcer;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Hungary, India, Poland, United States
- 2019-01-08